Biomarkers and tumour heterogeneity: Friends or enemies for differential therapy?
Joint meeting of the EAU Section of Urological Pathology (ESUP) and the EAU Section of Urological Research (ESUR)
-
Location:Room Paris, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session Major advances have been made in understanding the mechanisms of primary and acquired resistance to current agents in urogenital cancer, as well as in the identification and validation of relevant molecular targets. The integration of clinic-pathologic data with emerging techniques of molecular profiling-based treatment will represent the future of personalised therapeutic approach for urogenital cancer.
To be confirmed
To be confirmed